James Molloy

Jeffrey Kraws

Jonathan Aschoff

Robert LeBoyer

John Vandermosten

Laura Suriel

Vernon Bernardino

- GeoVax Labs, Inc. announced a **registered direct offering** with certain healthcare-focused institutional investors on **September 30, 2025**.  **[832489_0001437749-25-030125_ex_865351.htm:0]** 
- The offering involves the sale of **3,968,256 shares** of common stock (or equivalents) and warrants to purchase up to **11,904,768 shares** of common stock at a combined purchase price of **$0.63 per share** and accompanying warrant.  **[832489_0001437749-25-030125_ex_865351.htm:0]** 
- The gross proceeds from the offering are expected to be approximately **$2.5 million**, with net proceeds of approximately **$2,325,000** after deducting fees and expenses.  **[832489_0001437749-25-030125_ex_865351.htm:0]** **[832489_0001437749-25-030125_govx20250930_8k.htm:1]** 
- The company intends to use the net proceeds to **advance its product candidates**, including research and development, manufacturing, clinical studies, and working capital.  **[832489_0001437749-25-030125_ex_865351.htm:0]** **[832489_0001437749-25-030125_govx20250930_8k.htm:1]** 
- The warrants will have an exercise price of **$0.63 per share**, will be exercisable upon shareholder approval, and will expire **5 years** from shareholder approval.  **[832489_0001437749-25-030125_ex_865351.htm:0]** **[832489_0001437749-25-030125_govx20250930_8k.htm:1]** **[832489_0001437749-25-030125_ex_865347.htm:1]**

GeoVax Labs Announces $2.5 Million Registered Direct Offering

- GeoVax Labs is advancing its **GEO-CM04S1 vaccine** for immunocompromised COVID-19 patients, with clinical trial results showing its vaccine's immune response **exceeds mRNA vaccines**; notably, the **Pfizer arm of a chronic lymphocytic leukemia (CLL) trial was halted** as it did not meet desired endpoints, while GeoVax's vaccine exceeded them.  **[832489_2157883_1]** **[832489_2157883_2]** 
- The company plans to raise an **additional $12 million to $15 million by the end of 2025** to support the progress of its programs, which also include an mpox/smallpox vaccine and solid tumor therapy.  **[832489_2157883_2]** **[832489_2157883_3]** 
- GeoVax is actively communicating with the investment community to address perceived undervaluation, with some analysts suggesting a stock price of **$5 to $12 per share**.  **[832489_2157883_3]**

GeoVax Labs (GOVX)